CER Consultants & Clinical Evaluation Report CRO | EU MDR | Eclevar MedTech
Platinum Award · xShare & EUCROF 2026

Clinical Evaluation Reports that Notified Bodies accept the first time.

Whether you need a full service CRO or a senior CER consultant, Eclevar MedTech eliminates the root causes of Notified Body non conformities before the first draft reaches the reviewer: MEDDEV 2.7/1 rev.4 methodology, Article 61(4) equivalence, Annex XIV traceability and PMCF linkage, built in from day one.

0major non conformities across Eclevar managed CER submissions in 2024 and 2025
1 roundour target Notified Body review cycle
7 yrsof clinical evidence delivery across Europe
4therapeutic franchises: cardio, ortho, dental, wound care
Eclevar MedTech backed by investors Backed by private investors and venture capital. Funding & investors

Milo took the Platinum Award at the xShare & EUCROF Open Call.

In the xShare and European CRO Federation (EUCROF) Open Call for Clinical Research, the top Platinum Award went to Milo Health, the technology platform behind Eclevar's evidence and forecasting work, presented at the EUCROF 2026 conference in Amsterdam.

Milo Health receiving the Platinum Award on stage at the xShare and EUCROF Open Call Awards for Clinical Research
xShare × EUCROF·Amsterdam, 2 Feb 2026

Co-funded by the European Union

Platinum Award · xShare Open Call for Clinical Research, organised by EUCROF and co-funded by the European Union. Amsterdam, 2 February 2026.

Built against EU MDR 2017/745 MEDDEV 2.7/1 rev.4 MDCG 2020-13 Annex XIV Article 61(4) ISO 14155:2020
How can we help

Three ways sponsors work with us on clinical evaluation.

From a single remediation mandate to a fully outsourced clinical evaluation report, scope the engagement to the problem in front of you.

CER consultant for Notified Body deficiencies

You already have a major NCR or a deficiency letter. A senior consultant, backed by a former Notified Body reviewer, rebuilds the failing element and drafts the response: equivalence, SLR methodology, traceability or PMCF linkage.

NCR remediationQ&A responseCAPA

CRO for the full clinical evaluation report

Outsource the CER end to end: state of the art, MEDDEV 2.7/1 rev.4 literature review, equivalence, authoring and Notified Body Q&A, signed by expert clinicians and delivered as one consistent package with the SSCP.

Full authoringClass IIb / IIIExpert sign off

Integrated CER and PMCF strategy

Connect evidence generation to evaluation: PMCF surveys, registries and clinical investigations designed to close the exact gaps your clinical evaluation identifies, so each update cycle gets stronger, not longer.

PMCF surveysRegistriesAnnex XIV
The clinical evidence gap

Why most clinical evaluation reports fail the first Notified Body review.

If you are searching for a CRO or consultancy to help with your clinical evaluation, start here. A CER is not a writing exercise: it is an evidence architecture, and most submissions collapse at the same five load bearing points.

68%

Major NCR rate at first submission

More than two thirds of Class IIb and Class III CER submissions under EU MDR receive a major non conformity, from insufficient safety evidence to missing PMCF feedback loops.

9 mo

Average CE mark delay from CER cycles

Each Q&A round adds 3 to 4 months. For many sponsors, cumulative delays exceed nine months: lost market access for every month the device is not on the shelf.

Top 5 NCR root causes, EU MDR 2025

  • 01Lack of traceable Annex XIV residual risk to clinical evidence mapping.
  • 02Equivalence claimed without similarity demonstrated.
  • 03PMCF plan not linked to CER gaps.
  • 04Literature methodology fails MEDDEV 2.7/1 standards.
  • 05No state of the art benchmark defined.

The Eclevar difference: building backwards from the Notified Body checklist

Every CER Eclevar authors is built against the same assessment logic your Notified Body uses. Our senior team includes a former Notified Body reviewer who has assessed hundreds of packages and knows exactly which evidence gaps trigger a major NCR, so we close them before submission, not after.

The result across Eclevar managed CER submissions in 2024 and 2025: zero major non conformities.

Our CER architecture

How we eliminate every Notified Body non conformity.

Four structural answers to the four most common major NCRs. Each one is engineered into the document before authoring begins.

01

Annex XIV traceability matrix

NCR: no residual risk to evidence mapping

We build a complete matrix mapping every residual risk in the CER to a specific clinical evidence source. Notified Bodies cannot find a gap because there are no gaps.

02

Article 61(4) equivalence architecture

NCR: insufficient equivalence demonstration

We build the full three dimensional similarity matrix, technical, biological and clinical, before equivalence is claimed. No assertion is made without documentation.

03

MEDDEV 2.7/1 literature methodology

NCR: SLR methodology fails scrutiny

Full MEDDEV 2.7/1 Section 9 compliance: predefined strategy, explicit inclusion and exclusion criteria, PRISMA flow, and study appraisal with NICE or GRADE. No cherry picking.

04

PMCF plan closing CER gaps

NCR: PMCF plan not linked to specific gaps

Each PMCF objective is derived directly from a specific evidence gap identified in the clinical evaluation. The PMCF plan and the CER are two sides of a single document.

Q&A cycle comparison

From months of CAPA loops to one clean round.

Typical submission

3 to 4 rounds
  • ×Submit CER with a narrative literature review.
  • ×Notified Body: major NCR on SLR methodology.
  • ×CAPA: 2 to 3 months to revise the SLR.
  • ×Notified Body: major NCR on equivalence.
  • ×CAPA: 2 more months to rebuild equivalence.

Eclevar submission

1 round
  • Pre submission alignment with the Notified Body.
  • Submit the CER with its full evidence architecture.
  • Notified Body: minor clarification queries only.
  • Clarification response in 2 to 3 weeks.
  • Final approval.
CER service portfolio

Every CER deliverable, one integrated framework.

From state of the art definition to SSCP consistency, each deliverable is co-authored from the same verified source documents.

State of the art definition

Pre evaluation definition of the state of the art for the device category, establishing benchmarks before the search begins.

SoA analysisBenchmarking

Systematic literature review

MEDDEV 2.7/1 Section 9 compliant review with PRISMA flow and GRADE or NICE appraisal.

PRISMASection 9

Equivalence analysis

Full Article 61(4) coverage: technical, biological and clinical similarity, documented before the claim is made.

Art. 61(4)Similarity matrix

Data appraisal and integration

Critical appraisal of device specific data: clinical investigations, PMCF results and registries.

RCT / registryIntegration

CER authoring

Full MEDDEV 2.7/1 rev.4 authoring with the Annex XIV traceability matrix embedded in the document.

Annex XIVTraceability

SSCP and PMCF integration

Co-authored deliverables to ensure full internal consistency across the CER, the SSCP and the PMCF plan.

SSCPPMCF plan
Trusted by manufacturers

Clinical evidence delivered for global MedTech leaders.

Sponsors across cardiovascular, dental, renal, neuro and wound care rely on Eclevar for clinical evaluation, PMCF and Notified Body strategy.

RegenLab logo Nihon Kohden logo Meril Life Sciences logo Shofu Inc. logo Coloplast logo Vygon logo
Eclevar and Nihon Kohden teams together in Japan
Nihon Kohden · Class IIa EEG · Japan to EU MDR

Solving Notified Body deficiencies with PMCF and clinical strategy

Eclevar partnered with Nihon Kohden to resolve the deficiencies Notified Body reviewers raise on Japanese device files for the EEG-1200K: anticipating reviewer expectations, structuring the clinical strategy and linking PMCF evidence to the points reviewers challenge.

"Eclevar shared their expertise in a way that allowed us to create documentation perfectly adapted to our needs. The team responded promptly and flexibly."Product Manager, Nihon Kohden Corporation
Eclevar with the Meril Life Sciences team at a UK study meeting
Meril Life Sciences · Cardiovascular · UK

TAVI multi centre reimbursement study, 666 patients

A reimbursement clinical trial run as a multi centre study in the UK, supporting market access for Meril's TAVI platform with evidence designed for both regulators and payers.

Eclevar visiting Shofu Inc. headquarters in Japan
Shofu Inc. · Dental

Clinical evaluation and post market evidence for dental technologies

Dedicated clinical evaluation and post market evidence generation for advanced dental and restorative technologies.

Client conversation

RegenLab × Eclevar: a strategic alliance for regenerative medicine.

Eclevar manages all upcoming PMCF studies on chronic diabetic foot ulcer devices for RegenLab, present in 160 countries. "Eclevar, with its tailor made approach and advanced MILO Studio platform, represents a major strategic asset." Antoine Turzi, CEO, RegenLab.

RegenLab X Eclevar Medtech interview video thumbnail
YouTube · RegenLab X Eclevar MedtechOpen on YouTube ↗
Our CER expert team

Senior clinicians and a former Notified Body reviewer who de-risk your CER.

Documents are written the way a reviewer needs to read them, then challenged internally against Notified Body assessment logic before they ever leave the building.

Portrait of Pierre-Marie Boutanquoi, Head of Medical Writing at Eclevar MedTech

Pierre-Marie Boutanquoi

Head of Medical Writing · CER lead

Leads CER and PMCF authoring across franchises, with deep methodology expertise in MEDDEV 2.7/1 rev.4 literature review, equivalence files and Class III evidence packages.

Portrait of Prof. Mark DaCosta, COO and CMO Cardiovascular at Eclevar MedTech

Prof. Mark DaCosta

COO & CMO Cardiovascular · former Notified Body reviewer

Cardiac surgeon and former senior reviewer at a Notified Body (TUV SUD). Reviews every CER against the assessment frameworks reviewers actually apply, and leads pre submission alignment.

Portrait of Dr. Nikhil Khadabadi, CMO Orthopaedics and Spine at Eclevar MedTech

Dr. Nikhil Khadabadi

CMO · Orthopaedics & Spine

Senior clinical lead for Class IIb and Class III orthopaedic and spine implants, from state of the art definition to clinical data appraisal and benefit risk conclusions.

Portrait of Charline Petitdemange, Lead Clinical Project Manager at Eclevar MedTech

Charline Petitdemange

Lead Clinical Project Manager

Pilote la réalisation des investigations cliniques et études PMCF en Europe. Qualification des sites, monitoring, TMF, ISO 14155:2020. Master Ingénierie de la Santé (Université Grenoble Alpes). Parcours : recherche clinique, cardiovasculaire, usability medical devices.

Portrait of Sebastien Meier Piantanida, Chief Data Officer at Eclevar MedTech

Sébastien Meier Piantanida

Chief Data Officer

Leads clinical data management and the Milo platform, so PMCF and registry data feed the clinical evaluation with verified, consistent values.

Portrait of Karina Schönborn, Head of Partnerships at Eclevar MedTech

Karina Schönborn

Head of Partnerships

Your first point of contact: scopes the CER gap assessment, aligns stakeholders and keeps sponsors connected to the right expert at the right moment.

Expert guides

Read and unlock our clinical evaluation guides.

Practical references written by Eclevar's senior team for regulatory and clinical leaders preparing EU MDR submissions.

Reforming Clinical Evaluation of Medical Devices in Europe

Our expert guide on where clinical evaluation under EU MDR is heading, what Notified Bodies are signalling, and how sponsors should structure evidence now to stay ahead.

Free download · sent to your inbox

CER gap assessment, free and live

Prefer answers on your own file? Book a free 30 minute gap assessment: we review your current evidence against the Notified Body checklist and outline exactly what is required to reach approval in a single round.

Free · 30 minutes · no obligation
News & events · Where to meet us in 2026

Meet the team out in the field.

Where our consultants, including our former Notified Body expert, are presenting and what we are building. Come and find us, or book a call.

Eclevar MedTech at EuroPCR 2026 in Paris, May 19 to 22, with Chems Hachani, Prof. Mark DaCosta, Charline Petitdemange and Sebastien Meier Piantanida
Event : Paris : 19 to 22 May 2026

Meet us at EuroPCR 2026

The Eclevar team, including our former Notified Body expert, on what cardiovascular trials need to satisfy Notified Body review.

Book a meeting ↗
Speaker panel at CSI Frankfurt on 3 June 2026: Impact of MDR on introduction and innovation of devices, with Prof. Mark DaCosta
Speaker panel : Frankfurt : 3 June 2026

Impact of MDR on device innovation

Prof. Mark DaCosta, COO and former Notified Body expert, joins the CSI Frankfurt speaker panel on EU MDR and the introduction of new devices.

See the session ↗
Milo platform three way clinical trial cost and recruitment forecast interface
Platform : clinical trial forecasting

From an 8 week RFP to a 30 minute roadmap

Our award winning platform reads a protocol and returns three costed scenarios, swift, base and conservative, plus a recruitment forecast: the same rigour behind our CER evidence planning.

Discover Milo ↗
FAQ

Clinical evaluation report questions, answered.

What is a clinical evaluation report under EU MDR?

A clinical evaluation report (CER) is the document required by EU MDR 2017/745 that demonstrates, with clinical evidence, that a medical device is safe and performs as intended. It follows MEDDEV 2.7/1 rev.4 methodology and is assessed by your Notified Body as part of CE marking.

Why do most CERs receive major non conformities?

The most common root causes are missing Annex XIV residual risk to evidence traceability, equivalence claimed under Article 61(4) without a documented similarity demonstration, literature reviews that fail MEDDEV 2.7/1 Section 9 methodology, PMCF plans not linked to specific CER gaps, and no defined state of the art benchmark.

How does Eclevar demonstrate equivalence under Article 61(4)?

We build the full three dimensional similarity matrix covering technical, biological and clinical characteristics before any equivalence claim is made, so the Notified Body receives documentation rather than assertion.

Who writes and reviews the CER at Eclevar?

CERs are authored by our medical writing team led by Pierre-Marie Boutanquoi and reviewed against Notified Body assessment logic by senior clinicians including Prof. Mark DaCosta, a former senior reviewer at a Notified Body (TUV SUD), before submission.

How long does a Notified Body CER cycle take with Eclevar?

A typical submission goes through 3 to 4 question and answer rounds, with each round adding months. Eclevar targets a single round: pre submission alignment, a complete evidence architecture at first submission, then minor clarification queries only.

Should I hire a CER consultant or a CRO for my clinical evaluation?

It depends on scope. A consultant fits a targeted problem: one deficiency, one equivalence file, one methodology rebuild. A CRO fits when the CER depends on wider evidence work: literature review at scale, PMCF data, registries and Notified Body Q&A management. Eclevar covers both models: consultant level seniority, including a former Notified Body reviewer, with the medical writing team and data infrastructure of a CRO behind it.

Can Eclevar remediate a CER that already received a non conformity?

Yes. Remediation mandates start with a gap assessment of the deficiency letter, then we rebuild the failing element, equivalence, SLR methodology, traceability or PMCF linkage, and draft the response in the structure reviewers expect.

How are the CER and the PMCF plan connected?

Under EU MDR each PMCF objective should close a specific evidence gap identified in the clinical evaluation. Eclevar co-authors the CER and the PMCF plan as two sides of a single evidence strategy, with direct gap mapping.

Free · 30 minutes · no obligation

Your CER should be the last one with a major NCR.

Book a free clinical evaluation report gap assessment. We will review your current evidence and outline exactly what is required to achieve approval in a single round.

Book a free CER strategy call

Reforming Clinical Evaluation of Medical Devices in Europe